Celgene Corporation (NASDAQ:CELG) today announced ten programs selected
for funding under its Celgene Cancer Care Links™ program, an initiative
designed to support cancer healthcare capacity building in
resource-constrained countries around the world.

The programs selected are expected to support established institutions
partnering with in-country medical centers that provide essential cancer
care services including awareness and education, prevention, diagnosis
and care. The Celgene Cancer Care Links program is an initiative of
Celgene Global Health, which focuses on healthcare challenges facing
patients in developing parts of the world.

“Celgene Cancer Care Links is another program we have created to make a
meaningful impact for patients and healthcare systems around the world,”
said Mark J. Alles, Chairman and Chief Executive Officer of Celgene. “We
are excited to announce the first round of grants through this
initiative and wish these world-renowned organizations and institutions
great success.”

Recipients of Celgene Cancer Care Links grants include:

Program Title

Organization

Partner Institution

Standard of care for pediatric Kaposi Sarcoma in Lilongwe, Malawi

Baylor College of Medicine, Texas Children’s Hospital, Houston, TX

Baylor College of Medicine Children’s Foundation – Malawi

National cervical cancer prevention program in Haiti: scaling up a
pilot project

“The programs we are supporting through Celgene Cancer Care Links
address many important areas of cancer diagnosis and care,” said Joe
Camardo, M.D., Senior Vice President, Global Health and Corporate
Affairs Medical Strategy at Celgene. “For patients in
resource-constrained nations like these, programs addressing this area
fill a vital need in healthcare capacity.”

About Celgene Cancer Care Links™

Celgene Cancer Care Links is a grant program to support health care
capacity initiatives that enhance patient cancer care in
resource-constrained countries. Celgene Cancer Care Links is a
demonstration of Celgene's commitment to improving the lives of patients
worldwide.

The Celgene Cancer Care Links program is also featured in Access
Accelerated, a group of over 20 biopharmaceutical companies developing
innovative and sustainable solutions to improve access to
non-communicable disease treatment and care in low and middle-income
countries.In addition to each company committing to do more with
their individual programs, Access Accelerated also includes partnerships
with the World Bank and the Union of International Cancer Control.
Access Accelerated is part of the private sector’s commitment to
achieving the United Nations Sustainable Development Goal target to
reduce premature deaths from NCDs by 2030.

For more information on these programs, as well as Celgene’s Corporate
Responsibility and Global Health efforts, please visit the following
links:

Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
Pinterest,
LinkedIn,
Facebook
and YouTube.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. Celgene undertakes no
obligation to update any forward-looking statement in light of new
information or future events, except as otherwise required by law.
Forward-looking statements involve inherent risks and uncertainties,
most of which are difficult to predict and are generally beyond our
control. Actual results or outcomes may differ materially from those
implied by the forward-looking statements as a result of the impact of a
number of factors, many of which are discussed in more detail in
Celgene's Annual Report on Form 10-K and other reports filed with the
Securities and Exchange Commission.

Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.